Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 164 Breast Neoplasms 111 Colorectal Neoplasms 77 Neoplasms 65 Lung Neoplasms 61 Pancreatic Neoplasms 56 Stomach Neoplasms 52 Neoplasm Metastasis 51 Ovarian Neoplasms 45 Rectal Neoplasms 43 Esophageal Squamous Cell Carcinoma 38 Esophageal Neoplasms 38 Head and Neck Neoplasms 34 Squamous Cell Carcinoma of Head and Neck 32 Leukemia, Myeloid, Acute 32 Recurrence 26 Triple Negative Breast Neoplasms 25 Small Cell Lung Carcinoma 24 Precursor Cell Lymphoblastic Leukemia-Lymphoma 24 Glioblastoma 23 Colonic Neoplasms 23 Uterine Cervical Neoplasms 22 Nasopharyngeal Carcinoma 22 Lymphoma 21 Lymphoma, Non-Hodgkin 20 Fallopian Tube Neoplasms 20 Prostatic Neoplasms 17 Melanoma 17 Sarcoma 16 Leukemia 16

Interventions

Trastuzumab 3 pyrotinib 2 pertuzumab 2 Fulvestrant 2 tucatinib 1 palbociclib 1 disitamab vedotin 1 atezolizumab 1 RC48 antibody 1 Drug Therapy 1 Docetaxel 1 Capecitabine 1 Alpelisib 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Metastatic Breast Cancer × Drug Therapy × Clear all

NCT05188495 2022-01-12

HELP

Peking University Cancer Hospital & Institute

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡